Abstract 26
Recent emergence of direct acting antivirals (DAAs) targeting hepatitis C virus (HCV) 27 proteins has considerably enhanced the success of antiviral therapy. However, the appearance 28 of DAA resistant-associated variants is a cause of treatment failure, and the high cost of 29
DAAs renders the therapy not accessible in countries with inadequate medical infrastructures. 30 Therefore, search for new inhibitors and with lower cost of production should be pursued. In 31 this context, crude extract of Juncus maritimus Lam. was shown to exhibit high antiviral 32
activity against HCV in cell culture. Bio-guided fractionation allowed isolating and 33 identifying the active compound, dehydrojuncusol. A time-of-addition assay showed that 34 dehydrojuncusol significantly inhibited HCV infection when added after virus inoculation of 35 HCV genotype 2a (EC 50 = 1.35 µM). This antiviral activity was confirmed with a HCV 36 subgenomic replicon and no effect on HCV pseudoparticle entry was observed. Antiviral 37
activity of dehydrojuncusol was also demonstrated in primary human hepatocytes. No in vitro 38 toxicity was observed at active concentrations. Dehydrojuncusol is also efficient on HCV 39 genotype 3a and can be used in combination with sofosbuvir. Interestingly, dehydrojuncusol 40 was able to inhibit replication of two frequent daclatasvir resistant mutants (L31M or Y93H 41 in NS5A). Finally, resistant mutants to dehydrojuncusol were obtained and showed that HCV 42 NS5A protein is the target of the molecule. In conclusion, dehydrojuncusol, a natural 43 compound extracted from J. maritimus, inhibits infection of different HCV genotypes by 44 targeting NS5A protein and is active against HCV resistant variants frequently found in 45 patients with treatment failure. 46 47 Importance 48
Tens of millions of people are infected with hepatitis C virus (HCV) worldwide. Recently 49 marketed direct acting antivirals (DAAs) targeting HCV proteins have enhanced the efficacy of the treatment. However, due to its high cost, this new therapy is not accessible to the vast 51 majority of infected patients. Furthermore, treatment failures have also been reported due to 52 appearance of viral resistance. Here we report on the identification of a new HCV inhibitor, 53 dehydrojuncusol that targets HCV NS5A and is able to inhibit replication of replicons 54 harboring resistance mutations to anti-NS5ADAAs used in current therapy. 55
Dehydrojuncusol is a natural compound isolated from Juncus maritimus, a halophilic plant 56 species very common in the coastlines worldwide. This molecule might serve as a lead for the 57 development of new therapy more accessible to hepatitis C patients in the future. 58
INTRODUCTION 59
Hepatitis C is a major cause of chronic hepatitis often associated with complications, such as 60 liver cirrhosis and hepatocellular carcinoma (1, 2). A recent report estimates that 61 approximately 71.1 million people are infected with hepatitis C virus (HCV) worldwide (3). 62
To date no vaccine is available against HCV, mainly due to the diversity of viral isolates (4). 63
In recent decades, various treatments have been established. The first direct-acting antiviral 64 agents (DAA), targeting viral proteins were released in 2011. Since then, many DAA against 65 NS3/4A, NS5A and NS5B have been marketed, with high rates of sustained viral response 66 against all HCV genotypes and very few side effects (5). However, these treatments are very 67 expensive and not accessible to all people infected (6). Moreover, there is a risk of selecting 68 viral variants resistant to DAA leading to failure of the therapy, which will require new 69 treatments (7) . 70 HCV, a member of the Flaviviridae family, is an enveloped, single stranded RNA virus (8) 71 encoding a single polyprotein which is cleaved co-and post-translationally. Non-structural 72 proteins are involved in the replication of the viral genome and the production of new 73 infectious particles in infected cells. The HCV life cycle can be divided into three major steps: 74 entry, replication, and assembly/release. At each step, different sets of viral proteins and host 75 factors are involved. The replication of the RNA genome takes place in the 'membranous 76 web' which is composed of endoplasmic reticulum rearranged membranes (9). The replication 77 complex includes viral proteins NS3/4A, NS4B, NS5A and NS5B. 78
The current hepatitis C therapy is very efficient but leads to the appearance of resistant 79 associated substitutions (RASs). Some of the RASs are specific to a DAA, this is the case for 80 NS5B RASs but some of them appear independently of the DAA used, especially for NS3/4A 81 and NS5A RASs (10). Patients with NS5A resistant variant are very difficult to treat and re-82 treatment with a combination of anti-NS5B and anti-NS5A antivirals does not always lead to a highly sustained viral response. Moreover, these mutated viruses are persistent for years in 84 the blood serum (7). Lack of alternative therapy might be a problem for these patients in the 85
future. 86
Natural products from plant species maintain a strong position in the drug discovery (11). A 87 number of metabolites found in plants, among which are the phenolic compounds, are being 88 cited as antimicrobials and resistance-modifying agents (12, 13). Natural products often 89 remain a source of inspiration for medicinal chemistry, with semisynthetic modifications, or 90 pharmacophore with natural origin (14) . Numerous DAA from natural origin are now 91 described and are able to target different steps of the HCV infectious cycle (15). Crude 92 extracts from plants used in traditional medicine are also promising source of antiviral 93 molecules. However, only silymarin, a standardized extract of Milk thistle (Silybum 94 marianum (L.) Gaertn., Asteraceae) and some of its metabolites, silibinin A and B, a mixture 95 of two diastereoisomers of flavonolignans, are developed in clinical trials to be used in 96 hepatitis C infected patients (16). Extremophile plants either xerophytes (growing in arid 97 climate), or halophytes (growing in saline soils) are natural reservoirs of rare bioactive 98 compounds. By several molecular mechanisms, extremophile plants can resist to abiotic 99 stresses and to infections by producing phytoalexins (17). Rare compounds with unique or 100 common chemical structure present in extremophile plants might help to identify new DAA 101 against HCV with unexpected mechanism of action. 102
It is estimated that the new DAA therapy against hepatitis C will benefit to a very small part 103 of the patients (18). The use of plant extracts or compounds isolated from plant extracts 104 should render the therapy more accessible to many patients in developing countries. 105 Therefore, the search for such compounds and extracts is still needed to treat the vast majority 106 of the patients in the coming decades. In this context, we have screened halophilic and 107 xerophytic plant extracts from Tunisia for their anti-HCV activity. This led us to identify Juncus maritimus rhizome extract for its capacity to inhibit HCV infection (19) . By use of a 109 bio-guided fractionation approach, dehydrojuncusol, the active compound inhibiting HCV 110 infection was identified and its mechanism of action against HCV replication characterized. 111
112

RESULTS 113
Dehydrojuncusol present in the methylene chloride partition of J. maritimus rhizome 114 extract is an inhibitor of a post-entry step of HCV infection 115
We have previously screened sixteen plant extracts from eight different Tunisian 116 extremophile plants for the presence of antiviral compounds (19). The strongest antiviral 117 activity was observed for Juncus maritimus rhizome extract, a halophyte belonging to 118 Juncaceae family. The methylene chloride partition of J. maritimus rhizome extract was the 119 most active against HCV (19). To go further in the characterization of antiviral activity and 120 identify active compound(s) a bioguided fractionation was performed leading to the isolation 121 of two major phenanthrene derivatives (compounds 1 and 2). The chemical structures of these 122 two major compounds were determined by comparison of their spectroscopic data (NMR and 123 MS) with literature values. Compounds 1 and 2 were identified as two known phenanthrene 124 derivatives, respectively juncusol and dehydrojuncusol (20) ( Figure 1A ). The purity of these 125 compounds was checked by LC-UV-DAD (juncusol: 99.5%; dehydrojuncusol: 98.8%). Their 126 antiviral activity was determined against HCVcc of genotype 2a. A time-addition assay was 127 performed with the purified compounds at 10 µg/mL (corresponding to 37.5 and 37.8 µM for 128 juncusol and dehydrojuncusol respectively) added either during virus inoculation, or post-129 inoculation, or continuously during both steps. Epigallocatechin gallate (EGCG), an inhibitor 130 of HCV entry (21, 22) and Boceprevir, an inhibitor of NS3/4A protease, were used as 131 controls. As shown in Figure 1B , juncusol and dehydrojuncusol were both active against 132 post-inoculation and continuously during infection. Only juncusol significantly decreased the 134 number of cells ( Figure 1C ) showing limited cytotoxicity. Juncusol inhibited HCV infection 135 at the post-inoculation step, whereas dehydrojuncusol was active both at inoculation and post-136 inoculation steps. Dehydrojuncusol was the most active at the post-inoculation step with more 137 than 95% inhibition of HCV infection. As this compound was the most active, we decided to 138 further analyze its antiviral activity. 139
The antiviral effect of dehydrojuncusol was examined by measuring HCV infectious titers. A 140 dose-dependent decrease of the infectious titer was observed, with a 1-log 10 decrease at 2.2 141 µM confirming its high anti-HCV activity (Figure 2A) . A time-of-addition assay of 142 dehydrojuncusol was performed and confirmed that this compound was significantly more 143 active during a post-inoculation step ( Figure 2B ). No major effect of dehydrojuncusol was 144 observed when cells were pre-incubated with the compound 2h before inoculation or when it 145 was co-added with the virus. To measure the half maximal effective concentration EC 50 , a 146 dose-response inhibition experiment was then performed with Huh-7 cells incubated with 147 increasing concentrations of dehydrojuncusol at different steps of the infection, either during 148 inoculation, or post-inoculation or continuously ( Figure 2C ). The results show that the EC 50 149 of dehydrojuncusol was 1.35 µM when added continuously, 8.21 µM when added during 150 inoculation, and 1.53 µM when added post-inoculation, confirming the major effect of the 151 molecule at the post-inoculation step. The toxicity of the compound on Huh-7 cells was also 152 tested in parallel at different time points, 24h, 48h, and 72h. The results showed that the 153 cytotoxic concentration (CC 50 ) of dehydrojuncusol was approximately 75.6 µM ( Figure 2D) , 154 much higher than the active dose, yielding a selective index of 56. 155
Taken together, these results show that dehydrojuncusol inhibits predominantly a post-entry 156 step of the HCV infectious cycle, most likely the replication, and, to a lesser extent, an early 157 step of infection, potentially the entry step. To test the activity of dehydrojuncusol on replication independently of entry, Huh-7 cells 169 stably expressing a HCV replicon were used. This replicon, SGR-JFH1-NS5AGFP, expresses 170 a GFP-tagged NS5A. Due to some difficulties to purify dehydrojuncusol in sufficient quantity 171 from J. maritimus extract to perform all the tests, the methylene chloride partition containing 172 dehydrojuncusol was used. The replicon cells were incubated with methylene chloride 173 partition and lysed at different time points. Boceprevir and daclatasvir, two inhibitors of 174 NS3/4A protease and NS5A protein, respectively, were used as controls. The activity of the 175 molecules against HCV replication was determined by quantifying the expression of NS5A-176 GFP protein by western blots. As shown in Figure 3B infected Huh-7 cells treated for 48h with dehydrojuncusol or daclatasvir at different concentrations. A decrease of more than 2xLog 10 of HCV genomic RNA level was observed 184 with 10 µM dehydrojuncusol, similar to the decrease observed with daclatasvir, an NS5A 185 inhibitor, at 0.1 nM ( Figure 3C ). Finally, to determine the effect of dehydrojuncusol on other 186 genotypes, its antiviral activity was tested against a strain of genotype 3a. As shown in Figure  187 3D, dehydrojuncusol is able to inhibit HCVcc of genotype 3a with EC 50 = 9.91 µM. Taken 188 together, these results show that dehydrojuncusol is an inhibitor of HCV replication with an 189 activity that is not limited to HCV genotype 2a. 190
191
Dehydrojuncusol has no effect on bovine viral diarrhea virus (BVDV) and yellow fever 192
virus (YFV) infection 193
To determine if the antiviral activity of dehydrojuncusol is specific to HCV, we tested the 194 antiviral effect of the methylene chloride partition of J. maritimus against two other members 195 of the Flaviviridae family, YFV and BVDV. As shown in Figure 3E , no significant decrease 196 in infectivity was observed neither for YFV nor for BVDV after treatment with 10 µg/mL of 197 J. maritimus methylene chloride partition. At this concentration, a strong inhibition of HCV 198 infection was observed. This result shows that dehydrojuncusol is not active against all the 199 members of the Flaviviridae family suggesting that it could target HCV protein(s) directly or 200 a cellular factor specifically involved in HCV replication. 201 202
Dehydrojuncusol inhibits HCV infection in PHH 203
Primary human hepatocytes (PHH) are a more relevant human pre-clinical model available to 204 test the activity of an inhibitor on HCV infection. A dose-response experiment was performed 205 in PHH inoculated with JFH-1 and treated with dehydrojuncusol for 28h after inoculation. 206
The infectious titer of supernatants, negative-strand HCV RNA genome copy number and 207 cytotoxicity of treatments were assayed 72h post-infection. As shown in Figure 4A , a dose-dependent decrease of HCV titer was observed with dehydrojuncusol showing that the 209 molecule is able to inhibit HCV infection in PHH. Very interestingly, the EC 50 of 210 dehydrojuncusol in PHH was 1.14 µM, similar to the EC 50 calculated in Huh-7 cells, 1.35 211 µM. The results were confirmed by the quantification of negative-strand HCV RNA genome 212
( Figure 4B ) that shows a similar decrease in the presence of dehydrojuncusol. The results 213 presented in Figure 4C show that dehydrojuncusol is not cytotoxic in PHH at active 214 concentrations. 215 216
Dehydrojuncusol inhibits replication of HCV mutants resistant to NS5A inhibitors 217
Some patients treated with the newly approved DAA molecules targeting NS5A or NS5B 218 become resistant to the therapy due to the appearance of HCV resistant mutants. Once present 219 in patients, these resistant mutants are very difficult to eliminate, particularly for the resistant 220 mutants selected during a treatment with anti-NS5A molecules, like daclatasvir, ledipasvir or 221 ombitasvir. To determine if dehydrojuncusol could be active against HCV resistant mutants, 222
we generated mutated replicons harboring point mutation L31M or Y93H in NS5A. These 223 two mutations conferred resistance to NS5A targeting drugs, including daclatasvir, ledipasvir 224 and ombitasvir, in patients infected with HCV of different genotypes, and are often associated 225 with treatment failure (7, 10). Huh-7 cells harboring mutant replicons were incubated with 226 methylene chloride partition of J. maritimus, containing dehydrojuncusol, and lysed after 72h 227 of treatment. Daclatasvir and boceprevir, were used as controls. As shown in Figure 5A , in 228 the L31M and Y93H replicon cell lysates, the NS5A-GFP protein was detected after 72h of 229 treatment with daclatasvir showing that these replicons are resistant to daclatasvir at 0.5 nM. 230
When treated with boceprevir, NS5A-GFP was not detected showing that the mutants are still 231 sensitive to boceprevir, as expected. In cells expressing mutated replicons treated with 232 methylene chloride partition at 10 µg/mL, NS5A-GFP was not detected with the L31M mutant, showing that dehydrojuncusol is able to inhibit the replication of a daclatasvir-234 resistant mutant. However, it was still detectable at lower level with the Y93H daclatasvir-235 resistant mutant, showing that this mutant is less sensitive to dehydrojuncusol than L31M. To 236 quantify this antiviral activity, a dose-response experiment was performed on replicon cells 237 treated with either daclatasvir or dehydrojuncusol and the number of cells expressing NS5A-238 GFP after 72h of treatment was quantified. As shown in Figure 5B , the L31M mutant was 239 very sensitive to the dehydrojuncusol with an EC 50 of 0.22 µM similar to wild-type 0.40 µM, 240
whereas the Y93H daclatasvir-resistant was less sensitive to dehydrojuncusol than the wild-241 type replicon, (EC 50 of 3.62 µM), correlating with the results obtained by Western blot. 242
However, the EC 50 fold change between wild-type and Y93H replicon was only of 9, much 243 lower than the EC 50 fold change observed with daclastasvir ( Figure 5C ), which was calculated 244 to be over 100 for both mutants (24). 245
246
The target of dehydrojuncusol is NS5A 247
In order to identify the viral target of dehydrojuncusol, JFH1 resistant mutants were generated 248 by infecting Huh-7 cells with JFH1, followed by treatment with 5 × EC 50 of dehydrojuncusol, 249 for 3 weeks. Viral RNA was extracted every 3-4 days to follow the appearance of resistant 250 viruses (data not shown). Viral RNA extracted at day 21 was sequenced and three mutations 251 at the same amino-acid position of NS5A were detected, F28I, F28L, and F28V. These 252 mutations were individually inserted in the JFH1 genome by reverse genetic. The three 253 mutants exhibited a strong resistance to dehydrojuncusol, showing that the amino acid residue 254 F28 is required for the anti-HCV activity of dehydrojuncusol ( Figure 6A ). In parallel, we also 255 tested the resistance of these mutants toward daclatasvir. The F28I, F28L and F28V remained 256 sensitive to daclatasvir ( Figure 6B ). 257
Dehydrojuncusol can be used in combination with Sofosbuvir 259
The results presented ahead show that dehydrojuncusol encompasses many characteristics of 260 a DAA to be used in therapy. In order to determine the potential use of dehydrojuncusol in 261 combination with the known DAA, combination study of dehydrojuncusol and sofosbuvir, an Plants are known to be an important source of numerous bioactive compounds (14) . Here, we 273 highlighted the strong inhibition of HCV infection obtained in HCV in cell culture (HCVcc) 274 system by a bioactive molecule, dehydrojuncusol, isolated from a J. maritimus rhizomes 275 extract. More interestingly, we also showed that this natural product strongly inhibits the virus 276 in PHH, which is one of the most relevant human pre-clinical model for HCV infection. Many 277 different drugs are now available to cure hepatitis C, but in some patients, appearance of viral 278 variants resistant to the treatment makes them difficult to cure, especially for NS5A resistant 279 mutants. Unfortunately, the sets of marketed molecules available are not efficient to cure such 280 resistant viruses (7). In this work, we demonstrate that dehydrojuncusol has the capacity to 281 inhibit two NS5A resistant mutants appearing in patients treated with anti-NS5A inhibitors, 282 L31M and Y93H, which are two major resistant variants appearing after treatment with daclatasvir, ledipasvir or ombitasvir (7, 10). These mutants are often associated with 284 treatment failure. Therefore, dehydrojuncusol or molecules derived from dehydrojuncusol 285 might be of great interest in the future to cure patients with resistant variants and treatment 286 failure. Here, we demonstrate that dehydrojuncusol anti-HCV activity is not genotype specific 287 since this molecule is able to inhibit HCV genotype 3a in addition to genotype 2a. 288
Furthermore, we also show that dehydrojuncusol can be used in combination with sofosbuvir, 289 the most widely used DAA that targets NS5B polymerase. 290
Even if dehydrojuncusol is able to inhibit replication of HCV replicon harboring point 291 mutations in NS5A (L31M and Y93H), it seems likely that the viral target of this molecule is 292 NS5A. Dehydrojuncsuol resistant HCV mutants were obtained and we demonstrated that a 293 single mutation of NS5A F28 is responsible for the resistance to dehydrojuncusol. This amino 294 acid residue was mutated into three different amino acids, isoleucine, leucine, and valine and 295 each of them confers resistance to dehydrojuncusol. Phenylalanine 28 is one of the first 296 amino-acid residues of NS5A domain 1. This domain is the target of daclatasvir, ombitasvir 297 and ledispavir (26). Resistance mutations in NS5A at the position 28 have been already 298 described for genotype 1 (M28) which confer resistance to daclatasvir, ombitasvir or 299 ledipasvir (7, 10, 27, 28). For JFH1 genotype 2a, F28S resistance mutation has been observed 300 for daclatasvir (24) and ombitasvir (29). In this study, no other mutation than the one at 301 position F28 has been identified suggesting that dehydrojuncusol might interact with NS5A at 302 a site different than daclatasvir or other known anti-NS5A inhibitors. 303
Unexpectedly for a replication inhibitor, dehydrojuncusol also inhibits HCV infection when it 304 is added to the cells during virus contact and removed later on ( Figure 2B and 2C ). This 305 ability to inhibit an early step of HCVcc infection is probably not due to an inhibition of HCV 306 entry as this molecule is not active on HCVpp ( Figure 3A) . It is likely that this effect results 307 from dehydrojuncusol molecules that enter cells during viral inoculation, remain trapped 308 inside cells and are able to inhibit HCV replication afterwards. 309
The EC 50 of dehydrojuncusol is close to 1 µM, in the replicon, in the HCVcc system, and in 310 PHH, a concentration relatively low for a natural product. This molecule might serve as a 311 starting point for a study of structure activity relationships and drug design to increase its 312 antiviral capacity and reduce its EC 50 . It is rare that a compound is as active in Huh-7 as in 313
PHH. The EC 50 of dehydrojuncusol could even be decreased by 3xLog 10 Only a moderate anti-inflammatory activity has been shown for this natural product (33).
J. maritimus is a perennial plant which thrives in particular on saline soils. In the framework 333 of our study, this halophyte was collected in Tunisia, but J. maritimus is present worldwide in 334 the coast line of many different areas, including several European countries such as France. 335
Few traditional uses are mentioned for this plant in Tunisia, with the exception of its use in 336 making baskets and curtains. Its usage as an antiviral agent is a new opportunity for economic 337 valorization of this plant. One of the disadvantages of our study is that the part of the plant 338 used is not renewable (rhizomes), so the chemical synthesis of dehydrojuncusol or a more 339 active derivative could be an alternative. It would be also interesting to search for 340 dehydrojuncusol in other Juncus species and especially in parts of plant renewable, such as 341 aerial parts. Interestingly, this phenanthrene derivative has been previously isolated from the 342 aerial parts of Juncus species, such as J. acutus (34) and J. effusus (35), increasing its 343 potential for its use in low income countries. 344
In conclusion, we showed that dehydrojuncusol, an active compound present in J. maritimus 345 rhizomes, is a new DAA that targets HCV NS5A and inhibits replication of resistant viruses 346 appearing in patients treated with anti-NS5A inhibitors and responsible for treatment failure. The viral stocks were produced in Huh-7 cells. Huh-7 cells were infected with a pre-stock of 405
HCVcc in flasks. After 24h, 48h and 72h the supernatants of flasks were collected. The titer 406 of the stock was 5.10 6 and 5.10 5 focus forming unit (ffu)/mL for JFH1 and DBN3a respectively. For infection assay, Huh-7 cells, 6,000/well, seeded in 96-well plate were 408 inoculated with HCVcc at a multiplicity of infection (MOI) of 0.8 during 2h at 37°C then the 409 inoculum was removed and cells were incubated in complete culture medium for 28h at 37°C. 410
Compounds were added to cells either for 2h at 37°C before infection (preincubation 411 condition), for 2h at 37°C in the presence of the virus (inoculation condition), for 28h at 37°C For HCV infection, PHH were inoculated 3 days post-seeding at a MOI of 2 with a non-418 modified JFH1 virus (HCVcc), as previously described (38). After a 2h incubation at 37°C, 419 the inoculum was removed, and PHH were incubated in complete culture medium for 28h at 420 37°C at the indicated concentrations of dehydrojuncusol. The medium was then renewed 421 without treatment. Supernatants containing infectious HCVpc were harvested 3 days post-422 inoculation, and infectious titers were evaluated by a focus-forming assay on Huh-7 cells as 423 previously described (42). Intracellular levels of negative-strand HCV RNA were quantified 424 by a strand-specific reverse-transcription real-time polymerase chain reaction technique 425 described previously (threshold of detection, 25 copies/reaction) (43). The potential 426 cytotoxicity of dehydrojuncusol was assessed by measurement of the activity of lactate 427 dehydrogenase (LDH) released into culture supernatants, as previously described (23). 428
429
BVDV and YFV 430
Bovine viral diarrhea virus (BVDV, strain NADL) was produced in MDCK cells as 431 previously described (44). Yellow fever virus (YFV, strain 17D) was produced in SW13 cells.
Infection assays were performed with MDBK cells (BVDV) or Huh-7 cells (YFV) seeded in 433
96-well plates, at a MOI of 1.5 or 1, respectively. Cells were infected for 1 hour at 37°C. The 434 viral inoculum was removed and the cells were further cultured for either 15 hours (BVDV) 435 or 23 hours (YFV). Cells were fixed with paraformaldehyde 3% in PBS and subjected to 436 HCVcc, YFV and BVDV infected cells grown in 96-well plates were processed for 450 immunofluorescence detection of viral proteins, as previously described (46). Nuclei were 451 stained with 1 µg/mL of DAPI, and infected cells were detected by immunofluorescent 452 labeling of E1 envelope glycoprotein (HCV), E envelope protein (YFV) and NS3 protein 453 
Viability Assay 481
Huh-7 cells were plated in 96-well plates at a density of 6.000 cells/well and then were 482 incubated the next day in 100 μl of culture medium containing increasing concentrations of 483 dehydrojuncusol for either 24h, 48h, or 72h. An MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-484 carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]-based viability assay (Cell Titer 485 96 Aqueous non-radioactive cell proliferation assay, Promega) was performed as 486 recommended by the manufacturer. The absorbance of formazan at 490 nm is detected using 487 an ELISA plate reader (ELX 808 Bio-Tek Instruments Inc). Each measure was performed in 488 triplicate. 489
490
HCV replicon 491
The plasmid pSGR-JFH1 encoding a sub-genomic replicon of JFH-1 strain was obtained from 492
Dr T Wakita (48). A BglII and an NsiI restriction sites were inserted between codons Pro419 493 and Leu420 of NS5A, and the coding sequence of EGFP was then inserted between these two 494 sites. This position was previously shown to accept a GFP insertion in a sub-genomic replicon 495 of the Con1 strain (49). Mutations Leu31Met (L31M) and Tyr93His (Y93H) were inserted 496 independently by PCR. Plasmid pSGR-JFH1-NS5AGFP and PCR amplified DNA containing 497 mutated sequences were digested with NsiI and BglII restriction enzymes, and PCR fragment 498 inserted by ligation into the plasmid. All constructs were verified by sequencing. These 499 plasmids were in vitro transcribed before electroporation into Huh-7 cells. Cells that express 500 wild type and mutated replicons were selected for using 500 µg/mL of geneticin during 15 501 days and cultured in a medium containing 250 µg/mL of geneticin. 502 503
Replication assay 504
Huh-7 cells stably expressing wild type or mutated replicons were seeded in 24-well plates 505 and incubated with the different compounds for 24h, 48h and 72h. They were lysed in ice cold lysis buffer (Tris HCl 50mM, NaCl 100 mM EDTA 2 mM Triton-100 1% SDS 0.1%) on 507 ice for 20 min. Lysates were collected and 20 µg of proteins were analyzed by western 508 blotting using anti-NS5A and anti-β tubulin antibodies. Peroxidase-conjugated goat anti-509 mouse secondary antibody (Jackson Immunoresearch) was used for the revelation using ECL 510 western blotting substrate (Thermo Fischer Scientific). The intensity of the bands was 511 quantified using ImageJ software. 512
Wild-type, L31M and Y93H replicon cell lines were seeded in 96-well plates and incubated 513 with boceprevir, daclatasvir or methylene chloride partition at given concentration for 72h. 514
Cells were fixed with PFA 3% for 30 min. The cells were counted by labeling of nuclei with 515 DAPI (0.5 µg/mL). Number of GFP-positive cells was quantified with a Zeiss Axiophot 2 516 microscope equipped with a 40×/1.3 numerical aperture lens. Fluorescence signals were 517 analyzed as described previously. 518 519
Selection of a dehydrojuncusol-resistant virus and identification of resistance mutations 520
Huh-7 cells were infected with JFH1 followed by treatment with 5 × EC 50 (6.55 µM) of 521 dehydrojuncusol. Cells were split every 3-4 days in the presence of dehydrojuncusol at 6.55 522 µM and viral RNA was extracted in parallel to follow appearance of resistant viruses. At day 523 21, viral RNA was extracted and the genomic sequence of HCV from NS2 to NS5B was 524 amplified by RT-PCR and sequenced. Amino acid changes that arose during inhibitor 525 selection were identified by analysis of the DNA sequence compared to the initial and control 526 passages in the absence of drug. The identified mutations were reintroduced into the JFH1 527 plasmid by PCR mutagenesis, and the plasmids were sequenced. 528 529 530
Statistical Analysis 531
The results were presented as means ± SEM of three independent experiments performed in 532 triplicate. The statistical test used is a Kruskal Wallis nonparametric test followed by a 533
Dunn's multicomparison post hoc test with a confidence interval of 95% to identify individual 534 difference between treatments. P values < 0.05 were considered as significantly different from Huh-7 cells stably expressing subgenomic replicon SGR-JFH1-NS5AGFP wild-type or harboring L31M or Y93H mutation in NS5A that confer resistance to daclatasvir were incubated for 72h either with 0.5 nM daclatasvir, 1 µM boceprevir, or 10 µg/mL of methylene chloride partition of J. maritimus (J. mar. MeCl). DMSO 0.0001 % was used as a control. Cells were lysed and lysates subjected to SDS-PAGE followed by western blot revelation of GFP and tubulin. (B)(C) Huh-7 cells stably expressing subgenomic replicon SGR-JFH1-NS5AGFP wild-type or harboring L31M or Y93H mutation in NS5A that confer resistance to daclatasvir were incubated for 72h with increasing concentrations of dehydrojuncusol (B) or daclatasvir (C). Cells were fixed and the percentage of GFP positive cells was quantified, as a measure of replication. Replication of subgenomic replicon was expressed as a ratio to carrier control DMSO 0.0001 %. Data are means of values obtained in 3 independent experiments performed in triplicate. Error bars represent SEM. 
